The executive management team at healthcare IT company Allscripts Healthcare Solutions (MDRX)
has already accomplished quite a bit to its credit. Product quality has
improved, clients have better product roadmaps, and higher investments
in R&D should enhance the company's long-term competitiveness. The
company has also carved out a solid position in the emerging population
health space.
All of that said, Allscripts has just kept pace with Cerner (CERN) over the past one to two years, and lagged growth darling athenahealth (ATHN).
Not only is the healthcare IT space brutally competitive in the largely
penetrated acute care setting, but the company has not yet proven that
its transition to a recurring revenue model (including SaaS) will
support healthy margins. Allscripts does not look all that cheap, which
is quite common in the healthcare IT space, though the company's
relative valuation will hold more appeal to those investors who believe
management can deliver EBITDA growth in the high teens or low 20%'s in
the coming years.
Follow this link for more:
Allscripts Still In The Middle Of A Challenging Transition
No comments:
Post a Comment